As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly cautious about their next moves. In such a climate, penny stocks—often representing smaller or newer companies—can offer unique opportunities for those willing to explore beyond the blue-chip names. Despite being an outdated term, penny stocks remain relevant as they can combine value and growth potential, especially when backed by strong financials.

Top 10 Penny Stocks In The United States

Click here to see the full list of 753 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Precision Optics Corporation

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States, with a market cap of $28.64 million.

Operations: The company generates revenue of $18.68 million from its Surgical & Medical Equipment segment.

Market Cap: $28.64M

Precision Optics Corporation, with a market cap of US$28.64 million, is navigating challenges typical of penny stocks. Despite generating US$18.68 million in revenue from its Surgical & Medical Equipment segment, the company remains unprofitable with increasing losses over the past five years at 29% annually. Recent changes include appointing Buell Duncan to its board, enhancing strategic leadership potential amid ongoing financial adjustments like a US$5.09 million equity offering to bolster liquidity. While short-term assets cover liabilities and debt levels are satisfactory, cash runway concerns persist despite recent capital infusion efforts aimed at stabilizing operations.

• Click to explore a detailed breakdown of our findings in Precision Optics Corporation's financial health report.
• Understand Precision Optics Corporation's track record by examining our performance history report.

FibroBiologics

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: FibroBiologics, Inc. is a cell therapy and regenerative medicine company with a market cap of $40.17 million.

Operations: FibroBiologics, Inc. currently does not report any revenue segments.

Market Cap: $40.17M

FibroBiologics, Inc., with a market cap of US$40.17 million, exemplifies the high-risk, high-reward nature of penny stocks. As a pre-revenue entity in the biotech sector, it focuses on fibroblast-based therapies for chronic diseases. Despite having more cash than debt and short-term assets exceeding liabilities, its financial runway is limited to nine months without additional capital infusion. Recent developments include completing a master cell bank for clinical trials and securing funding through shelf registrations and private placements to support ongoing research initiatives. The company's share price remains volatile amid strategic efforts to advance its therapeutic pipeline.

• Dive into the specifics of FibroBiologics here with our thorough balance sheet health report.
• Gain insights into FibroBiologics' future direction by reviewing our growth report.

Milestone Scientific

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Milestone Scientific Inc. is a biomedical technology company that patents, designs, develops, and commercializes injection technologies for medical, dental, and cosmetic use globally with a market cap of $77.89 million.

Operations: The company generates revenue primarily from its Dental segment, which accounts for $8.75 million, and a smaller contribution from its Medical segment at $0.13 million.

Market Cap: $77.89M

Milestone Scientific Inc., with a market cap of US$77.89 million, operates in the biomedical technology sector, focusing on injection technologies. Despite being unprofitable, it shows financial stability with short-term assets of US$10.7 million exceeding both short and long-term liabilities. The company recently launched its CompuFlo Epidural System at Pain Doctors Medical LLC, enhancing patient safety and procedural efficiency through advanced technology. While the management team is relatively new with an average tenure of 1.2 years, Milestone's revenue is projected to grow by 17.53% annually despite its volatile share price and negative return on equity.

• Get an in-depth perspective on Milestone Scientific's performance by reading our balance sheet health report here.
• Review our growth performance report to gain insights into Milestone Scientific's future.

Make It Happen

• Unlock more gems! Our US Penny Stocks screener has unearthed 750 more companies for you to explore.Click here to unveil our expertly curated list of 753 US Penny Stocks.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:POCI NasdaqGM:FBLG and NYSEAM:MLSS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com